重度盆腔子宫内膜异位症术后应用内分泌药物疗效观察

目的探讨米非司酮、内美通及达那唑用于重度盆腔子宫内膜异位症（内异症）术后辅助治疗的疗效及安全性.方法回顾分析154例重度盆腔内异症术后随访资料,比较术后应用米非司酮、内美通、达那唑及未用药组的复发率和副反应发生率.结果米非司酮组、内美通组、达那唑组复发率分别为10.5%、9.3%、12.2%,低于未用药组37.5%（P〈0.05）.米非司酮组及内美通组副反应发生率显著低于达那唑组 （P〈0.05）.结论米非司酮、内美通及达那唑用于盆腔内异症的术后辅助治疗是有效的,米非司酮及内美通副反应较少.

Clinical observation on the effects of mifepristone, gestrinone and danazol in the treatment for postoperative patients with severe pelvic endometriosis

Objective To investigate the effects and safety of mifepristone, gestrinone and Danazol in the treatment for postoperative patients with severe pelvic endometriosis.Methods 154 severe pelvic endometriosis cases were analyzed retrospectively. Of these cases, 38 were administered mifepristone(mifepristone group),43 were administered gestrinone(gestrinone group), 41 were administered danazol(danazol group) and other 32 cases with no hormone drugs(control group). Recurrence rates,side effect rates were compared among these groups .Results The recurrence rates of mifepristone group, gestrinone group and danazol group were 10.5% , 9.3% and 12.2%,respectively, which were significantly lower than that of control group(P< 0.05).The side effect rate of mifepristone group and gestrinone group were significantly lower than that of danazol group (P< 0.05).Conclusion The treatment of mifepristone, gestrinone and danazol on postoperative patients with pelvic endometriosis is effective. Mifepristone and gestrinone caused less side effects than that of danazol.